These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 24429027)

  • 1. The prognostic value of P-cadherin in non-muscle-invasive bladder cancer.
    Wang P; Lin SL; Zhang LH; Li Z; Liu Q; Gao JX; Liu DM; Bo JJ; Huang YR
    Eur J Surg Oncol; 2014 Mar; 40(3):255-9. PubMed ID: 24429027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
    Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
    Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
    Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
    Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HMOX1 is an important prognostic indicator of nonmuscle invasive bladder cancer recurrence and progression.
    Yim MS; Ha YS; Kim IY; Yun SJ; Choi YH; Kim WJ
    J Urol; 2011 Feb; 185(2):701-5. PubMed ID: 21168882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PFKFB4 as a prognostic marker in non-muscle-invasive bladder cancer.
    Yun SJ; Jo SW; Ha YS; Lee OJ; Kim WT; Kim YJ; Lee SC; Kim WJ
    Urol Oncol; 2012; 30(6):893-9. PubMed ID: 21396842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
    Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J
    Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
    Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
    J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
    Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
    Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
    Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
    Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of RING box protein-1 (RBX1) associated with poor prognosis of non-muscle-invasive bladder transitional cell carcinoma.
    Wang W; Qiu J; Liu Z; Zeng Y; Fan J; Liu Y; Guo Y
    J Surg Oncol; 2013 Jun; 107(7):758-61. PubMed ID: 23609182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
    Mahnken A; Kausch I; Feller AC; Krüger S
    Oncol Rep; 2005 Oct; 14(4):1065-70. PubMed ID: 16142373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.
    Lin YL; Wang YL; Ma JG; Li WP
    J Exp Clin Cancer Res; 2014 Aug; 33(1):68. PubMed ID: 25927589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late recurrence and progression in non-muscle-invasive bladder cancers after 5-year tumor-free periods.
    Matsumoto K; Kikuchi E; Horiguchi Y; Tanaka N; Miyajima A; Nakagawa K; Nakashima J; Oya M
    Urology; 2010 Jun; 75(6):1385-90. PubMed ID: 20110108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of angiogenesis in nonmuscle invasive bladder cancer as defined by microvessel density after immunohistochemical staining for CD34.
    Ajili F; Kacem M; Tounsi H; Darouiche A; Enayfer E; Chebi M; Manai M; Boubaker S
    Ultrastruct Pathol; 2012 Oct; 36(5):336-42. PubMed ID: 22574784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer.
    Fahmy M; Mansure JJ; Brimo F; Yafi FA; Segal R; Althunayan A; Hicks J; Meeker A; Netto G; Kassouf W
    Hum Pathol; 2013 Sep; 44(9):1766-72. PubMed ID: 23623586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.
    Otto W; Breyer J; Herdegen S; Eder F; Bertz S; May M; Mayr R; Lausenmeyer EM; Denzinger S; van Rhijn BW; Burger M; Hartmann A
    Int Urol Nephrol; 2017 Mar; 49(3):431-437. PubMed ID: 28035618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of tumor recurrence: a strong predictor of stage progression in initially diagnosed nonmuscle invasive bladder cancer.
    Tanaka N; Kikuchi E; Matsumoto K; Miyajima A; Nakagawa K; Oya M
    J Urol; 2011 Feb; 185(2):450-5. PubMed ID: 21167533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review.
    Rouprêt M; Seisen T; Compérat E; Larré S; Mazerolles C; Gobet F; Fetissof F; Fromont G; Safsaf A; d'Arcier BF; Celhay O; Validire P; Rozet F; Irani J; Soulié M; Pfister C;
    J Urol; 2013 Jun; 189(6):2069-76. PubMed ID: 23201497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
    Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A
    Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of bladder neck involvement on progression in patients with primary non-muscle invasive bladder cancer: a prospective validation study.
    Kobayashi S; Fujii Y; Koga F; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Masuda H; Kihara K
    Urol Oncol; 2014 Jan; 32(1):38.e29-36. PubMed ID: 23702087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.